# StemCyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stemcyte

- Industry: Healthcare
- Headquarters: Covina, US
- Website: www.stemcyte.com
- Total disclosed funding: $21M
- Latest round: Series C (Jul 14, 2006)
- Investors on record: 5

## About

StemCyte Inc. is a biotechnology company specializing in cord blood banking, providing critical services for the collection, processing, and storage of umbilical cord stem cells for therapeutic use.Founded in 1997 and headquartered in Covina, US, StemCyte Inc. operates in the biotechnology sector, focusing on stem cell banking. The company has engaged in five funding deals, with the most recent being a VENTURE DEBT round in November 2010 amounting to USD 2.50 mn, raising a total of USD 9.00 mn. The firm had notable investments from Peninsula Bank. The leadership includes CEOs Jonas Wang, Kenneth Giacin, and Tong-Young Lee, overseeing its operations and growth.StemCyte specializes in cord blood banking, offering both private and public banking services for umbilical cord stem cells. Their core product involves the collection, processing, and storage of stem cells derived from newborns' umbilical cords, which can be used to treat over 80 diseases, including various cancers and blood disorders. StemCyte provides a convenient three-step service for parents: enrollment, collection at the hospital during delivery, and transfer to their laboratory for processing. The company serves a diverse client base, including expectant parents, healthcare providers, and hospitals primarily in North America and parts of Asia. Their focus on maintaining a large, ethnically diverse inventory of publicly donated cord blood units enhances their contributions to global medical research and clinical trials, making them a key player in this niche market.StemCyte generates revenue through service fees associated with the collection, processing, and long-term storage of cord blood stem cells. Clients typically engage with the firm by enrolling in a service plan, which includes the shipment of a collection kit to their home. After collection, parents coordinate the transfer of the collected stem cells to StemCyte's facility for processing. The pricing structure includes various plans that cater to different needs, ensuring access to their services for a wide range of families. Notably, StemCyte emphasizes their flagship MaxCell Processing method, which has contributed to their impressive transplant record, allowing them to be involved in a considerable portion of worldwide cord blood transplants.In November 2010, StemCyte Inc. secured VENTURE DEBT financing from Peninsula Bank, which is intended to support the enhancement of their service offerings and expansions into new markets. The company is focused on developing new products and services designed to improve their cord blood processing capabilities. Additionally, StemCyte plans to expand its reach into international markets, particularly targeting regions in Asia by 2025, to increase their global footprint in the stem cell banking sector.

## Funding rounds

- Series C, Jul 14, 2006, $9M — National Technology Enterprises Company, Sycamore Ventures, Amkey Ventures
- Series D, May 29, 2002, $5M — Springboard-Harper Investment, Sycamore Ventures, Millennium Group
- Series C, Mar 22, 2002, $7.4M — Springboard-Harper Investment, Millennium Group

## Investors

- Springboard-Harper Investment (https://capitalatlas.ai/funds/springboard-harper-investment) — Series C, Series D
- Millennium Group — Series C, Series D
- Sycamore Ventures (https://capitalatlas.ai/funds/sycamore-ventures) — Series D, Series C
- National Technology Enterprises Company — Series C
- Amkey Ventures (https://capitalatlas.ai/funds/amkey-ventures) — Series C